Login to Your Account



Xcovery goes head-to-head against Xalkori in phase III NSCLC trial

By Marie Powers
News Editor

Thursday, June 30, 2016

Xcovery Inc. launched the phase III trial of X-396, its lead ALK inhibitor, as a first-line treatment in patients with ALK+ NSCLC.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription